Frontlight ResearchEarly access
CompletedPhase 1
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
Key facts
- Who runs it
- Seqirus
- Where
- Australia2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 96 people enrolled
- Started
- 5 Oct 2023
- Ended
- 13 Oct 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- sa-mRNA vaccine Dose 1
- sa-mRNA vaccine Dose 2
- sa-mRNA vaccine Dose 3
- Placebo
- Record updated
- 27 November 2024
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Individuals 18 to 49 years of age OR 65 to 85 years of age, inclusive on the day of informed consent
- Individuals with body mass index (BMI) between 18 and 32 kg/m2, inclusive, at screening
- Individuals who can comply with study procedures including follow-up
Who cannot take part
- Female participants of childbearing potential who are pregnant, lactating, or who have not adhered to a specified set of highly effective contraceptive methods from at least 30 days prior to informed consent and who do not plan to do so for the duration of the study
- Receipt or planning to receive blood products, non-study vaccine, influenza vaccine, mRNA-platform vaccine within different timeframes; previous or from study vaccination
- Progressive, unstable, or uncontrolled clinical conditions
- Known hypersensitivity or allergy to any study vaccine component
- Known history of Guillain-Barré syndrome or other demyelinating disease
- Condition representing a contraindication to vaccination or blood draw
- Abnormal function of immune system due to clinical condition, medications, or radiotherapy
- Baseline abnormal clinically significant ECG, laboratory safety parameters or vital signs
- Male participants who have not adhered to using barrier contraception such as a condom during at least 60 days after each vaccination, to prevent semen transfer to their sexual partners and prevent pregnancy of a female partner
- Plan to donate blood products (other than for this study), sperm, ova, tissues, or organs up to 60 days following the last vaccination
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and magnitude of the post-vaccination antibody response will be evaluated at different timepoints as compared to placebo in healthy adults.
Read full original descriptionShow less
Approximately 96 evaluable subjects will be enrolled in this study; n=72 receiving investigational vaccine and n=24 receiving placebo.
The study has a screening period (Day -28 to Day -1), a treatment period (Day 1 to Day 43) and a follow-up period (Day 44 to Day 202).
The 4 groups in the trial
- sa-mRNA vaccine dose 1Treatment being tested
- sa-mRNA vaccine dose 2Treatment being tested
- sa-mRNA vaccine dose 3Treatment being tested
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying MRNA Influenza Vaccine in Healthy Adults
- Record updated
- 27 November 2024